<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542462</url>
  </required_header>
  <id_info>
    <org_study_id>2015-2754</org_study_id>
    <nct_id>NCT02542462</nct_id>
  </id_info>
  <brief_title>Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study</brief_title>
  <official_title>Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized clinical trial that aims to evaluate the potential effects
      of the first dose of rotavirus vaccines on gastrointestinal motility and anatomy and blood
      and stool cytokine responses. It will also assess the association between these outcomes and
      the pattern of the shedding of vaccine strain rotavirus in the stool. Infants will be
      randomized to one of four arms: monovalent rotavirus vaccine (Rotarix®, RV1) alone, RV1 with
      other recommended vaccines, pentavalent rotavirus vaccine (RotaTeq®, RV5) alone, or RV5 with
      other recommended vaccines. Data derived from the pilot study will be used to assess the
      feasibility of conducting a larger scale study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy infants 6-13 weeks of age will be randomized (1:1:1:1) to receive either, RV1 alone,
      RV1 with Advisory Committee on Immunization Practices (ACIP) routinely recommended
      immunizations (Diphtheria, Tetanus and Pertussis (DTaP), Haemophilus influenza type b (Hib),
      pneumococcal conjugate (PCV13), Hepatitis B (HBV) and inactivated polio (IPV)), RV5 alone or
      RV5 with ACIP routinely recommended immunizations. Imaging study personnel and parents will
      be blinded to the rotavirus vaccine type; parents will be informed about the rotavirus
      vaccine type at the completion of the study. Up to 100 infants will be enrolled.

      Recruitment and enrollment will occur prior to the first clinic visit. There will be four
      study visits including the recruitment/enrollment visit and three clinic visits. Infants will
      be randomized to either RV1, RV1 plus other immunizations, RV5 alone, or RV5 plus other
      immunizations. Clinic Visit 1 (day 0) will include blood, saliva, stool and breast milk
      collection . The MRI and ultrasound will be performed prior to vaccination. Children will
      receive the immunizations to which they are randomized. Imaging personnel and parents will be
      blinded to rotavirus vaccine type; they will be informed about other vaccines administered. A
      second MRI and ultrasound will be performed at Clinic Visit 2 (day 5) and blood and stool
      samples collected. Parents will be unblinded at the completion of Clinic Visit 3 (day 14).
      Arrangements will be made to get remaining doses of same rotavirus vaccine. Daily stool
      samples will be collected at home during the 15 day study period (on vaccination day 0 and
      for next 14 days). A memory aid will be completed to collect reactogenicity data on days 0
      and for the next 14 days. Remaining stools and reactogenicity data from parents will be
      collected at Visit 3.

      The investigators will assess blood and stool cytokine responses and intestinal anatomy and
      motility after rotavirus vaccination by comparing pre-vaccination with post-vaccination
      responses in the study infants. Cytokines and intestinal anatomy and motility will be
      assessed at baseline (Visit 1, the day of vaccine receipt) and 5 days after vaccination
      (Visit 2). For both blood and stool, the following cytokines will be tested: IL-2, IL-6,
      IL-7, IL-8, IL-15, INF-γ and TNF-α. Additional biomarkers may be studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Effects of RV1 and RV5 With or Without Other Routine Immunizations on Gastrointestinal Anatomy</measure>
    <time_frame>4- 6 days</time_frame>
    <description>Number of subjects with an increase in the number of abdominal lymph nodes, as measured by abdominal ultrasound, or an increase of 1 mm or more of terminal ileum wall thickness, as measured by abdominal MRI, from Day 0 (Visit 1) to Day 4-6 (Visit 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Feasibility of Conducting a Larger Scale Study as Determined by Study Recruitment Rates (Number of Participants Eligible/Participants Who Enrolled)</measure>
    <time_frame>15 months</time_frame>
    <description>Study will be determined to be feasible on a larger scale if 10% or more of eligible subjects enroll in the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Feasibility of Conducting a Larger Scale Study as Determined by the Percentage of Participants Who Completed All Study Visits</measure>
    <time_frame>15 months</time_frame>
    <description>Study will be determined to be feasible on a larger scale if 70% or more of randomized subjects complete all study visits and remain in the study until completion</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Intussusception</condition>
  <condition>Rotavirus Infections</condition>
  <arm_group>
    <arm_group_label>Rotarix® alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>monovalent rotavirus vaccine (Rotarix®, RV1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotarix®,with other routine vaccines</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>monovalent rotavirus vaccine (Rotarix®, RV1), plus additional immunizations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RotaTeq®, alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pentavalent rotavirus vaccine (RotaTeq®, RV5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RotaTeq®,with other routine vaccines</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pentavalent rotavirus vaccine (RotaTeq®,RV5) plus additional immunizations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rotarix®,</intervention_name>
    <description>Single oral dose of licensed rotavirus vaccine given alone</description>
    <arm_group_label>Rotarix® alone</arm_group_label>
    <other_name>Rotavirus vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rotarix®, with other routine vaccines</intervention_name>
    <description>Single oral dose of licensed rotavirus vaccine given with other routine vaccines</description>
    <arm_group_label>Rotarix®,with other routine vaccines</arm_group_label>
    <other_name>Rotavirus vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RotaTeq®,</intervention_name>
    <description>Single oral dose of licensed rotavirus vaccine given alone</description>
    <arm_group_label>RotaTeq®, alone</arm_group_label>
    <other_name>Rotavirus vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RotaTeq®, with other routine vaccines</intervention_name>
    <description>Single oral dose of licensed rotavirus vaccine given with other routine vaccines</description>
    <arm_group_label>RotaTeq®,with other routine vaccines</arm_group_label>
    <other_name>Rotavirus vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. healthy infant 6 to 13 weeks (12 weeks and 6 days) of age at day of rotavirus vaccine
             administration

          2. free of obvious health problems as established by medical history and confirmed with
             infant's primary physician prior to Visit 1

          3. parent/legal guardian willing to have infant feed from a bottle for contrast

          4. parent/legal guardian willing and capable of signing informed consent

          5. parent/legal guardian and infant expected to be available for entire study

          6. parent/legal guardian can be reached by telephone

          7. parent/legal guardian expresses willingness to complete study procedures and receive 2
             month immunizations, according to recommended schedule

        Exclusion Criteria:

          1. gestational age of &lt;37 weeks

          2. infant unable to fast for 4 hours prior to MRI procedure

          3. receipt of any vaccine except initial HBV (must have at least 28 days between HBV and
             Visit 1 to be included)

          4. history of severe allergic reaction to HBV vaccine

          5. contraindications for any of the routine vaccines

               1. Severe Combined Immune Deficiency

               2. history of intussusception

          6. precautions for either RV1 or RV5 (may interfere with study outcomes)

             a. altered immunocompetence i. infants with primary and acquired immunodeficiency
             states, cellular immunodeficiency, hypogammaglobulinemic and dysgammaglobulinemic
             states ii. infants with blood dyscrasias, leukemia, lymphomas, or other malignant
             neoplasms affecting the bone marrow or lymphatic system iii. infants on
             immunosuppressive therapy (including high-dose systemic corticosteroids) iv. infants
             who are HIV-exposed or infected b. acute gastroenteritis c. moderate or severe acute
             illness with or without fever d. pre-existing chronic gastrointestinal diseases (e.g.,
             congenital malabsorption syndromes, Hirschsprung's disease, or short-gut syndrome) e.
             infants with spina bifida or bladder exstrophy (latex rubber is contained in the RV1
             oral applicator)

          7. sensitivity to latex (latex rubber is contained in the RV1 oral applicator)

          8. febrile illness within previous 14 days (axillary temperature of 100.4◦ F or higher)

          9. history of vomiting (forceful expulsion of partially digested milk/food) and/or
             diarrhea (3 watery stools) within 14 days of Visit 1

         10. receipt of any steroids, immunoglobulins, other blood products/transfusion

         11. receipt of non-steroidal anti-inflammatory drugs in previous 72 hours (may affect
             cytokine response)

         12. receipt of an antipyretic medication (acetaminophen or ibuprofen) within 72 hours
             prior to the first dose of rotavirus vaccine or is already planning to administer a
             prophylactic antipyretic medication on the day of and the day following vaccination
             (this exclusion does not apply if the caretaker indicates he/she might administer
             antipyretics after vaccination to reduce a fever)

         13. is enrolled or plans to enroll in another clinical trial with an investigational
             product while participating in this study (observational studies are allowed)

         14. any condition which, in the opinion of the investigators, may post a health risk to
             the subject or interfere with the MRI or vaccine evaluation

         15. currently receiving medication for gastroesophageal reflux (GERD) or any other
             gastrointestinal condition including colic

         16. infant who is a relative of any research study personnel

         17. allergy to barium

         18. failed newborn hearing screening

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary A. Staat, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Broder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hosptital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <results_first_submitted>May 29, 2018</results_first_submitted>
  <results_first_submitted_qc>July 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2018</results_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mechanisms for intussusception</keyword>
  <keyword>rotavirus vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotavirus Infections</mesh_term>
    <mesh_term>Intussusception</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT02542462/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>During the study period, there were 252 children screened and of these, 238 were eligible for enrollment. These subjects were identified through screening at a primary care clinic and through advertisement</recruitment_details>
      <pre_assignment_details>43 of 144 enrolled participants withdrew prior to randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rotarix® Alone</title>
          <description>monovalent rotavirus vaccine (Rotarix®, RV1)
Rotarix®,: Single oral dose of licensed rotavirus vaccine given alone</description>
        </group>
        <group group_id="P2">
          <title>Rotarix®,With Other Routine Vaccines</title>
          <description>monovalent rotavirus vaccine (Rotarix®, RV1), plus additional immunizations
Rotarix®, with other routine vaccines: Single oral dose of licensed rotavirus vaccine given with other routine vaccines</description>
        </group>
        <group group_id="P3">
          <title>RotaTeq®, Alone</title>
          <description>pentavalent rotavirus vaccine (RotaTeq®, RV5)
RotaTeq®,: Single oral dose of licensed rotavirus vaccine given alone</description>
        </group>
        <group group_id="P4">
          <title>RotaTeq®,With Other Routine Vaccines</title>
          <description>pentavalent rotavirus vaccine (RotaTeq®,RV5) plus additional immunizations
RotaTeq®, with other routine vaccines: Single oral dose of licensed rotavirus vaccine given with other routine vaccines</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rotarix® Alone</title>
          <description>monovalent rotavirus vaccine (Rotarix®, RV1)
Rotarix®,: Single oral dose of licensed rotavirus vaccine given alone</description>
        </group>
        <group group_id="B2">
          <title>Rotarix®,With Other Routine Vaccines</title>
          <description>monovalent rotavirus vaccine (Rotarix®, RV1), plus additional immunizations
Rotarix®, with other routine vaccines: Single oral dose of licensed rotavirus vaccine given with other routine vaccines</description>
        </group>
        <group group_id="B3">
          <title>RotaTeq®, Alone</title>
          <description>pentavalent rotavirus vaccine (RotaTeq®, RV5)
RotaTeq®,: Single oral dose of licensed rotavirus vaccine given alone</description>
        </group>
        <group group_id="B4">
          <title>RotaTeq®,With Other Routine Vaccines</title>
          <description>pentavalent rotavirus vaccine (RotaTeq®,RV5) plus additional immunizations
RotaTeq®, with other routine vaccines: Single oral dose of licensed rotavirus vaccine given with other routine vaccines</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" lower_limit="6" upper_limit="10.6"/>
                    <measurement group_id="B2" value="8" lower_limit="6" upper_limit="10.7"/>
                    <measurement group_id="B3" value="8.2" lower_limit="6.1" upper_limit="10.1"/>
                    <measurement group_id="B4" value="8.4" lower_limit="6.1" upper_limit="10.4"/>
                    <measurement group_id="B5" value="8.2" lower_limit="6" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age at birth (weeks)</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" lower_limit="37" upper_limit="41"/>
                    <measurement group_id="B2" value="38.8" lower_limit="37" upper_limit="41"/>
                    <measurement group_id="B3" value="38.9" lower_limit="37" upper_limit="42"/>
                    <measurement group_id="B4" value="38.8" lower_limit="37" upper_limit="41"/>
                    <measurement group_id="B5" value="38.8" lower_limit="37" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birthweight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="1.8" upper_limit="3.7"/>
                    <measurement group_id="B2" value="3" lower_limit="1.9" upper_limit="3.7"/>
                    <measurement group_id="B3" value="3" lower_limit="1.8" upper_limit="4.1"/>
                    <measurement group_id="B4" value="3" lower_limit="2.3" upper_limit="3.7"/>
                    <measurement group_id="B5" value="3" lower_limit="1.8" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Effects of RV1 and RV5 With or Without Other Routine Immunizations on Gastrointestinal Anatomy</title>
        <description>Number of subjects with an increase in the number of abdominal lymph nodes, as measured by abdominal ultrasound, or an increase of 1 mm or more of terminal ileum wall thickness, as measured by abdominal MRI, from Day 0 (Visit 1) to Day 4-6 (Visit 2)</description>
        <time_frame>4- 6 days</time_frame>
        <population>Subjects had an abdominal MRI followed by an abdominal ultrasound prior to receiving vaccines at Day 0 (Visit 1). They returned 4-6 days later for follow up MRI and Ultrasound post vaccination (Visit 2) Terminal ileum thickness was measured and compared pre-post. Abdominal lymph nodes seen on ultrasound were compared pre-post</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix® Alone</title>
            <description>monovalent rotavirus vaccine (Rotarix®, RV1)
Rotarix®,: Single oral dose of licensed rotavirus vaccine given alone</description>
          </group>
          <group group_id="O2">
            <title>Rotarix®,With Other Routine Vaccines</title>
            <description>monovalent rotavirus vaccine (Rotarix®, RV1), plus additional immunizations
Rotarix®, with other routine vaccines: Single oral dose of licensed rotavirus vaccine given with other routine vaccines</description>
          </group>
          <group group_id="O3">
            <title>RotaTeq®, Alone</title>
            <description>pentavalent rotavirus vaccine (RotaTeq®, RV5)
RotaTeq®,: Single oral dose of licensed rotavirus vaccine given alone</description>
          </group>
          <group group_id="O4">
            <title>RotaTeq®,With Other Routine Vaccines</title>
            <description>pentavalent rotavirus vaccine (RotaTeq®,RV5) plus additional immunizations
RotaTeq®, with other routine vaccines: Single oral dose of licensed rotavirus vaccine given with other routine vaccines</description>
          </group>
        </group_list>
        <measure>
          <title>The Effects of RV1 and RV5 With or Without Other Routine Immunizations on Gastrointestinal Anatomy</title>
          <description>Number of subjects with an increase in the number of abdominal lymph nodes, as measured by abdominal ultrasound, or an increase of 1 mm or more of terminal ileum wall thickness, as measured by abdominal MRI, from Day 0 (Visit 1) to Day 4-6 (Visit 2)</description>
          <population>Subjects had an abdominal MRI followed by an abdominal ultrasound prior to receiving vaccines at Day 0 (Visit 1). They returned 4-6 days later for follow up MRI and Ultrasound post vaccination (Visit 2) Terminal ileum thickness was measured and compared pre-post. Abdominal lymph nodes seen on ultrasound were compared pre-post</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Terminal Ileum increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph node increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The test is to see a difference among the four groups and the pre to post change of the primary outcomes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2</p_value>
            <p_value_desc>P value for the number of subjects with an increase of 1 mm or more of terminal ileum from pre to post was 0.2</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The test is to see a difference among the four groups and the pre to post change of the primary outcomes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3</p_value>
            <p_value_desc>P value for change in the number of subjects with an increase in number of lymph nodes from pre to post was 0.3.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Feasibility of Conducting a Larger Scale Study as Determined by Study Recruitment Rates (Number of Participants Eligible/Participants Who Enrolled)</title>
        <description>Study will be determined to be feasible on a larger scale if 10% or more of eligible subjects enroll in the study</description>
        <time_frame>15 months</time_frame>
        <population>During the study period, there were 252 children screened and of these, 238 were eligible for enrollment. These subjects were identified through screening at a primary care clinic and through advertisement.</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>Infants were randomized to one of four arms: monovalent rotavirus vaccine (Rotarix(r) RV1) alone, RV1 with other recommended vaccines, pentavalent rotavirus vaccine (RotaTeq(r) RV5) alone, or RV5 with other recommended vaccines</description>
          </group>
        </group_list>
        <measure>
          <title>The Feasibility of Conducting a Larger Scale Study as Determined by Study Recruitment Rates (Number of Participants Eligible/Participants Who Enrolled)</title>
          <description>Study will be determined to be feasible on a larger scale if 10% or more of eligible subjects enroll in the study</description>
          <population>During the study period, there were 252 children screened and of these, 238 were eligible for enrollment. These subjects were identified through screening at a primary care clinic and through advertisement.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Feasibility of Conducting a Larger Scale Study as Determined by the Percentage of Participants Who Completed All Study Visits</title>
        <description>Study will be determined to be feasible on a larger scale if 70% or more of randomized subjects complete all study visits and remain in the study until completion</description>
        <time_frame>15 months</time_frame>
        <population>All randomized subjects, irrespective of arm assignment</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>Infants were randomized to one of four arms: monovalent rotavirus vaccine (Rotarix(r) RV1) alone, RV1 with other recommended vaccines, pentavalent rotavirus vaccine (RotaTeq(r) RV5) alone, or RV5 with other recommended vaccines</description>
          </group>
        </group_list>
        <measure>
          <title>The Feasibility of Conducting a Larger Scale Study as Determined by the Percentage of Participants Who Completed All Study Visits</title>
          <description>Study will be determined to be feasible on a larger scale if 70% or more of randomized subjects complete all study visits and remain in the study until completion</description>
          <population>All randomized subjects, irrespective of arm assignment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 days</time_frame>
      <desc>solicited adverse events included fever, diarrhea, vomiting, irritability and hematochezia. Parents of infants filled out a memory aid for 15 days recording any of these events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rotarix® Alone</title>
          <description>monovalent rotavirus vaccine (Rotarix®, RV1)
Rotarix®,: Single oral dose of licensed rotavirus vaccine given alone</description>
        </group>
        <group group_id="E2">
          <title>Rotarix®,With Other Routine Vaccines</title>
          <description>monovalent rotavirus vaccine (Rotarix®, RV1), plus additional immunizations
Rotarix®, with other routine vaccines: Single oral dose of licensed rotavirus vaccine given with other routine vaccines</description>
        </group>
        <group group_id="E3">
          <title>RotaTeq®, Alone</title>
          <description>pentavalent rotavirus vaccine (RotaTeq®, RV5)
RotaTeq®,: Single oral dose of licensed rotavirus vaccine given alone</description>
        </group>
        <group group_id="E4">
          <title>RotaTeq®,With Other Routine Vaccines</title>
          <description>pentavalent rotavirus vaccine (RotaTeq®,RV5) plus additional immunizations
RotaTeq®, with other routine vaccines: Single oral dose of licensed rotavirus vaccine given with other routine vaccines</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Three looser than normal stools a day</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>One episode of vomiting</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Axillary temperature equal or greater to 99.5 Fahrenheit</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Crying more than usual</description>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="25"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a pilot study to assess the feasibility of conducting the outlined study and was not powered to detect differences in the anatomy pre-versus post immunization.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nancy Back RN MPH</name_or_title>
      <organization>Cincinnati Childrens Hospital Medical Center</organization>
      <phone>513-636-2479</phone>
      <email>Nancy.Back@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

